Uptown Research Institute Logo Banner

Bipolar Mania: Inpatient

Purpose of this Study: This study examines if Brexpiprazole is safe and effective in treating manic episodes that occur with Bipolar 1 Disorder. The study medicine is approved for use in schizophrenia, prescribed as Rexulti.

Learn more and Sign Up for this Study

Design of Study: This is an inpatient study. Participants are required to remain in the hospital for 3-4 weeks and must agree to stop current medications used to treat their Bipolar Disorder. Participants will receive Brexpiprazole or a placebo.

Length of Study: Approximately 8 weeks. (including a 3-4 week inpatient hospital stay).

Qualified Study Participants Will Receive:

  • Study-related care, inpatient care, and office visits at no cost
  • Investigational study medication at no cost
  • $75 compensation per visit

Am I Eligible for the Study?

  • Aged 18 - 65 years old
  • Diagnosed with Bipolar 1 and experiencing an acute manic episode
  • History of at least one prior manic episode that required intervention or hospitalization
  • Medically stable with a stable living residence
Note: These are not the only eligibility criteria for this clinical research study, and other criteria may exclude you.

Why Should You Participate? All new medicines are tested in clinical trials. You may also help others by advancing science, and you may gain access to a new treatment.

Interested in Participating? If you are interested in joining this study, please fill out the form below to provide your contact information, or call our office at (773) 989-8313 x 2 and leave a message on our screening line. A member of our staff will call you back within 24 hours and will conduct a short phone screen to determine if you should visit our office for further evaluation.

Studies Form
Please write or copy and paste the study name listed above here.
Please let us know any additional information here.
Sending

Bipolar Depression: Outpatient

Purpose of this Study: This study examines if a new medication is safe and effective in treating patients with Bipolar disorder who are currently depressed.

Learn more and Sign Up for this Study

Design of Study: This is an outpatient study and all participants will receive either the study medication or a placebo. Participants on Depakote or Lithium may stay on these medications throughout the study.

Length of Study: Nine (9) visits over 10 weeks.

Qualified Study Participants Will Receive:

  • Study-related care and office visits at no cost
  • Medication at no cost
  • $75 compensation per visit

Am I Eligible for the Study?

  • Aged 18 - 65 years old
  • Diagnosis of Bipolar Disorder
  • Current depressive episode lasting from 2 weeks to 6 months
  • Medically stable with a stable living residence
Note: These are not the only eligibility criteria for this clinical research study, and other criteria may exclude you.

Why Should You Participate? Clinical trials are how all new medicines are tested. These trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. You may also help others by advancing science and may gain access to a new treatment.

Interested in Participating? If you are interested in joining this study, please fill out the form below to provide your contact information, or call our office at (773) 989-8313 x 2 and leave a message on our screening line. A member of our staff will call you back within 24 hours and will conduct a short phone screen to determine if you should visit our office for further evaluation.

Studies Form
Please write or copy and paste the study name listed above here.
Please let us know any additional information here.
Sending

Post Traumatic Stress Disorder - Military Related: Outpatient

Purpose of this Study: This study examines the safety and effectiveness of the study drug, cyclobenzaprine, for the management of patients with military-related post-traumatic stress disorder (PTSD).

Learn more and Sign Up for this Study

Design of Study: This is an outpatient study open to individuals with military-related PTSD. Subjects will receive either the study medication or a placebo (“sugar pill”). At the end of the study, all participants have the option to continue on the active study medication.

Length of Study: 12 Weeks; with an option to rollover into a treatment only study at the end.

Qualified Study Participants Will Receive:

  • Study-related care and office visits at no cost
  • Medication at no cost
  • $75 compensation per visit

Am I Eligible for the Study?

  • Aged 18 - 75 years old
  • A diagnosis of military-related PTSD, and can show proof of service since 2001
  • Willing and able to withdraw from prohibited medications for the duration of the study
  • Medically stable with a stable living residence
Note: These are not the only eligibility criteria for this clinical research study, and other criteria may exclude you.

Why Should You Participate? This study offers state-of-the-art care tailored to adults with military-related PTSD at no cost to the participant. You may also help others by advancing science.

Interested in Participating? If you are interested in joining this study, please fill out the form below to provide your contact information, or call our office at (773) 989-8313 x 2 and leave a message on our screening line. A member of our staff will call you back within 24 hours and will conduct a short phone screen to determine if you should visit our office for further evaluation.

Studies Form
Please write or copy and paste the study name listed above here.
Please let us know any additional information here.
Sending

Extended-release Injection Treatment for Schizophrenia: Outpatient

Purpose of this Study: This study is being conducted to evaluate the efficacy, safety, and tolerability of different doses and durations (one month or two months) of risperidone given by injection as compared to placebo (no active ingredient) for use as a potential maintenance treatment in adults with schizophrenia. This study hopes to determine if the study drug prevents the worsening of the signs and symptoms of schizophrenia

Learn more and Sign Up for this Study

Design of Study: This is a randomized, double-blind, placebo-controlled study.

Length of Study: The total study duration for a subject will be approximately one year with the possibility of continuing on the same medication in a follow-up open-label study.

Qualified Study Participants Will Receive:

  • Study-related care and office visits at no cost
  • Medication at no cost
  • $75.00 per completed office visit; $30 per completed telephone visit

Am I Eligible for the Study?

  • Aged 18 - 65 years old
  • Diagnosed with schizophrenia
  • Has been responsive to an antipsychotic treatment (other than clozapine) in the past year
  • Willing to take “add-on” medication
  • Medically stable with a stable living residence
Note: These are not the only eligibility criteria for this clinical research study, and other criteria may exclude you.

Why Should You Participate?

  • Receive the newest and latest treatments in psychiatry.
  • Help yourself and others by contributing to medical research.
  • Receive study-related care and medication at no cost to you or your insurance provider.
  • Financial compensation for participation.
  • Remember: every single medication that is currently used for psychiatric care was once studied as part of a clinical trial.
  • Interested in Participating? If you are interested in joining this study, please click on the “Sign Up” button below to provide your contact information, or call our office at (773) 989-8313 x 2 and leave a message on our screening line. A member of our staff will call you back conduct a short phone screen to determine if you should visit our office for further evaluation.

    Studies Form
    Please write or copy and paste the study name listed above here.
    Please let us know any additional information here.
    Sending

Improving Cognition in Schizophrenia: Outpatient

Purpose of this Study: This study is being conducted to evaluate if the study drug may improve ability to remember, think clearly, and/or solve problems (cognitive skills) when taken with regular antipsychotics.

Learn more and Sign Up for this Study

Design of Study: This is a randomized, double-blind, placebo-controlled study. All participants remain on their baseline antipsychotic.

Length of Study: The total study duration for a subject will be approximately 20 weeks.

Qualified Study Participants Will Receive:

  • Study-related care and office visits at no cost
  • Medication at no cost
  • $75.00-$150 per completed office visit; $25 per completed telephone visit

Am I Eligible for the Study?

  • Aged 18-50 years old, male or female
  • Primary diagnosis is schizophrenia, with no hospitalization within 3 months
  • Medically stable with stable residence
  • Willing to take an add on medication
  • Must identify a support person to act as an informant as needed (this person interacts with patient at least twice weekly)
Note: These are not the only eligibility criteria for this clinical research study, and other criteria may exclude you.

Why Should You Participate?

  • Receive the newest and latest treatments in psychiatry.
  • Help yourself and others by contributing to medical research.
  • Receive study-related care and medication at no cost to you or your insurance provider.
  • Financial compensation for participation.
  • Remember: every single medication that is currently used for psychiatric care was once studied as part of a clinical trial..
  • Interested in Participating? If you are interested in joining this study, please click on the “Sign Up” button below to provide your contact information, or call our office at (773) 989-8313 x 2 and leave a message on our screening line. A member of our staff will call you back conduct a short phone screen to determine if you should visit our office for further evaluation.

    Studies Form
    Please write or copy and paste the study name listed above here.
    Please let us know any additional information here.
    Sending

Long-acting Injection Treatment for Schizophrenia

Purpose of this Study: This study is being conducted to evaluate the bioequivalence of the study drug compared with Invega Sustenna. It is expected to have similar efficacy and safety compared with Invega Sustenna, and to be a cost saving treatment since schizophrenia and schizoaffective disorder require continuous and long-term therapy with antipsychotics.

Learn more and Sign Up for this Study

Design of Study: This is a randomized, double-blind, bioequivalence study. There will be three study treatment periods to allow for crossover of study product and reference product. Each treatment period will have three doses of test or reference product each.

Length of Study: The total study duration will be approximately 22 months, including a screening period of up to 28 days and three 12-week (84 days) treatment periods.

Qualified Study Participants Will Receive:

  • Study-related care, inpatient care, and office visits at no cost.
  • Investigational study medication at no cost.
  • $75 compensation per visit.
  • Free transportation to and from appointments.

Am I Eligible for the Study?

  • Aged 18 to 64 years
  • Diagnosed with Schizophrenia or Schizoaffective Disorder
  • Have an identified reliable caregiver
  • Medically stable with a stable living residence
Note: These are not the only eligibility criteria for this clinical research study, and other criteria may exclude you.

Why Should You Participate?

  • Receive the newest and latest treatments in psychiatry.
  • Help yourself and others by contributing to medical research.
  • Receive study-related care and medication at no cost to you or your insurance provider.
  • Financial compensation for participation.
  • Remember: every single medication that is currently used for psychiatric care was once studied as part of a clinical trial.
  • Interested in Participating? If you are interested in joining this study, please click on the “Sign Up” button below to provide your contact information, or call our office at (773) 989-8313 x 2 and leave a message on our screening line. A member of our staff will call you back conduct a short phone screen to determine if you should visit our office for further evaluation.

    Studies Form
    Please write or copy and paste the study name listed above here.
    Please let us know any additional information here.
    Sending